An environmental Escherichia albertii strain, DM104, induces protective immunity to Shigella dysenteriae in guinea pig eye model
- PMID: 24452425
- DOI: 10.1007/s00284-014-0522-y
An environmental Escherichia albertii strain, DM104, induces protective immunity to Shigella dysenteriae in guinea pig eye model
Abstract
The environmental Escherichia albertii strain DM104, which cross-reacts serologically with Shigella dysenteriae was assessed for pathogenic properties, immunogenicity, and protective efficacy in different animal models to evaluate it as a vaccine candidate against S. dysenteriae, which causes the severe disease, shigellosis. The DM104 isolate was found to be non-invasive and did not produce any entero- or cyto-toxins. The strain also showed negative results in the mouse lethal activity assay. The non-pathogenic DM104 strain gave, however, a high protective efficacy as an ocularly administered vaccine in the guinea pig eye model against S. dysenteriae type 4 challenge. It also induced a high titer of serum IgG against S. dysenteriae type 4 whole cell lysate and lipopolysaccharide. Taken together, all these results indicate a good potential for the use of the DM104 as a live vaccine candidate against shigellosis.
Similar articles
-
Protection against shigellosis caused by Shigella dysenteriae serotype 4 in guinea pigs using Escherichia albertii DM104 as a live vaccine candidate strain.Acta Microbiol Immunol Hung. 2017 Jun 1;64(2):151-164. doi: 10.1556/030.64.2017.015. Epub 2017 Jun 9. Acta Microbiol Immunol Hung. 2017. PMID: 28597684
-
Oral immunization of Escherichia albertii strain DM104 induces protective immunity against Shigella dysenteriae type 4 in mouse model.Acta Microbiol Immunol Hung. 2021 Jul 21. doi: 10.1556/030.2021.01431. Online ahead of print. Acta Microbiol Immunol Hung. 2021. PMID: 34292874
-
Live non-invasive Shigella dysenteriae 1 strain induces homologous protective immunity in a guinea pig colitis model.Microbiol Immunol. 2011 Oct;55(10):683-93. doi: 10.1111/j.1348-0421.2011.00371.x. Microbiol Immunol. 2011. PMID: 21806676
-
Shigellosis: the current status of vaccine development.Curr Opin Infect Dis. 2008 Jun;21(3):313-8. doi: 10.1097/QCO.0b013e3282f88b92. Curr Opin Infect Dis. 2008. PMID: 18448978 Review.
-
Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis.Hum Vaccin Immunother. 2019;15(6):1401-1408. doi: 10.1080/21645515.2019.1606971. Epub 2019 May 9. Hum Vaccin Immunother. 2019. PMID: 31070988 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical